|
US4925919A
(en)
*
|
1984-04-25 |
1990-05-15 |
Roland Mertelsmann |
Purified interleukin 2
|
|
US4992271A
(en)
*
|
1982-09-23 |
1991-02-12 |
Cetus Corporation |
Formulation for lipophilic IL-2 proteins
|
|
US4853332A
(en)
*
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
|
US4569790A
(en)
*
|
1984-03-28 |
1986-02-11 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
|
|
EP0158487B1
(en)
*
|
1984-04-09 |
1991-08-28 |
Takeda Chemical Industries, Ltd. |
Stable composition of interleukin-2
|
|
US4908433A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Uses of interleukin-2
|
|
US4908434A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Process for preparing purified interleukin-2
|
|
US4572798A
(en)
*
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
|
GB8508340D0
(en)
*
|
1985-03-29 |
1985-05-09 |
Creighton T E |
Production of protein
|
|
US5425940A
(en)
*
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
DE3621828A1
(de)
*
|
1986-06-28 |
1988-01-14 |
Biotest Pharma Gmbh |
Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
|
|
US4683293A
(en)
*
|
1986-10-20 |
1987-07-28 |
Phillips Petroleum Company |
Purification of pichia produced lipophilic proteins
|
|
CA1339757C
(en)
*
|
1987-04-16 |
1998-03-17 |
Robert F. Halenbeck |
Production of purified biologically active, bacterially produced recombinant human csf-1
|
|
US4929700A
(en)
*
|
1987-04-16 |
1990-05-29 |
Cetus Corporation |
Production of purified, biologically active, bacterially produced recombinant human CSF-1
|
|
US4931543A
(en)
*
|
1987-05-11 |
1990-06-05 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2
|
|
US4961969A
(en)
*
|
1987-05-11 |
1990-10-09 |
Cetus Corporation |
Process for recovering microbially produced interferon-β
|
|
ATE156491T1
(de)
*
|
1987-05-11 |
1997-08-15 |
Chiron Corp |
Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
|
|
US4801691A
(en)
*
|
1987-05-15 |
1989-01-31 |
International Minerals & Chemical Corp. |
Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
|
|
JP2669859B2
(ja)
*
|
1987-08-04 |
1997-10-29 |
協和醗酵工業株式会社 |
タンパク質の再活性化法
|
|
US5759815A
(en)
*
|
1988-02-11 |
1998-06-02 |
Creative Biomolecules, Inc. |
Production of platelet derived growth factor (PDGF) an muteins thereof
|
|
CA1340586C
(en)
*
|
1988-09-23 |
1999-06-08 |
Cetus Corporation |
Process for recovering microbially produced interferon-beta
|
|
JP2517100B2
(ja)
*
|
1989-03-08 |
1996-07-24 |
協和醗酵工業株式会社 |
ヒト顆粒球コロニ―刺激因子活性を有する蛋白質の精製法
|
|
US5204256A
(en)
*
|
1989-09-06 |
1993-04-20 |
Behringwerke Aktiengesellschaft |
Process for the purification of plasminogen activator inhibitor 2 (pai-2)
|
|
JPH05501500A
(ja)
*
|
1989-10-18 |
1993-03-25 |
クリエイティブ・バイオマリキュールズ・インコーポレーテッド |
TGF―βの生合成構築物
|
|
GB8927546D0
(en)
*
|
1989-12-06 |
1990-02-07 |
Ciba Geigy |
Process for the production of biologically active tgf-beta
|
|
US5830452A
(en)
*
|
1990-11-20 |
1998-11-03 |
Chiron Corporation |
Method for enhancing the anti-tumor therapeutic index of interleukin-2
|
|
US5252708A
(en)
*
|
1990-11-23 |
1993-10-12 |
Roussel Uclaf |
Preparation process for a protein containing at least one intramolecular disulphide bridge by oxidation, at a pH of less than 5.0 of corresponding reduced recombinant protein
|
|
IT1245063B
(it)
*
|
1991-04-12 |
1994-09-13 |
Ferruzzi Ricerca & Tec |
Procedimento per l'ossidazione di carboidrati
|
|
US5466781A
(en)
*
|
1991-05-24 |
1995-11-14 |
Chiron Therapeutics |
Process for purifying bacterially produced M-CSF
|
|
US5288931A
(en)
*
|
1991-12-06 |
1994-02-22 |
Genentech, Inc. |
Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
|
|
FR2684878B1
(fr)
*
|
1991-12-12 |
1994-02-11 |
Roussel Uclaf |
Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
|
|
US20030171292A1
(en)
*
|
1992-06-01 |
2003-09-11 |
Creasey Abla A. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
|
US6063764A
(en)
*
|
1992-06-01 |
2000-05-16 |
Washington University & Chiron Corp. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
|
AU687763B2
(en)
*
|
1992-10-20 |
1998-03-05 |
Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service |
Interleukin-6 receptor antagonists
|
|
CN1113389A
(zh)
*
|
1993-08-04 |
1995-12-13 |
西巴-盖尔基股份公司 |
高分子量的脱硫水蛭素
|
|
US5663304A
(en)
*
|
1993-08-20 |
1997-09-02 |
Genentech, Inc. |
Refolding of misfolded insulin-like growth factor-I
|
|
US5545723A
(en)
*
|
1994-03-15 |
1996-08-13 |
Biogen Inc. |
Muteins of IFN-β
|
|
TW517059B
(en)
|
1994-07-25 |
2003-01-11 |
Ciba Geigy Ag |
New process for the production of biologically active protein
|
|
DE19547933A1
(de)
*
|
1995-12-22 |
1997-06-26 |
Boehringer Mannheim Gmbh |
Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
|
|
AU735459B2
(en)
|
1997-01-30 |
2001-07-12 |
University Of Virginia Patent Foundation |
Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
|
|
US7270809B2
(en)
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
|
ATE375363T1
(de)
|
1997-07-14 |
2007-10-15 |
Bolder Biotechnology Inc |
Derivate des wachstumshormons und verwandte proteine
|
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
GB9806632D0
(en)
*
|
1998-03-28 |
1998-05-27 |
Stevenson Robert |
Peptide factor
|
|
AU775937B2
(en)
*
|
1999-01-14 |
2004-08-19 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
|
BR0213293A
(pt)
*
|
2001-10-15 |
2004-12-21 |
Chiron Corp |
Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
|
|
US20050008616A1
(en)
|
2003-07-11 |
2005-01-13 |
Schering Aktiengesellschaft |
Recombinant human interferon-beta-1b polypeptides
|
|
AU2004287879C1
(en)
|
2003-11-04 |
2011-05-26 |
Novartis Vaccines And Diagnostics, Inc. |
Antagonist anti-CD40 monoclonal antibodies and methods for their use
|
|
MXPA06010587A
(es)
*
|
2004-03-17 |
2007-03-29 |
Chiron Corp |
Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
|
|
EP2586788B1
(en)
|
2007-07-09 |
2017-11-29 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
|
EP2207890A4
(en)
*
|
2007-10-05 |
2010-12-15 |
Barofold Inc |
HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
|
|
CA2759370C
(en)
|
2009-04-30 |
2020-02-11 |
Peter Schotte |
Method for the production of domain antibodies
|
|
SG176963A1
(en)
|
2009-06-22 |
2012-02-28 |
Amgen Inc |
Refolding proteins using a chemically controlled redox state
|
|
LT3660032T
(lt)
|
2009-06-25 |
2026-02-25 |
Amgen Inc. |
Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
GB201101794D0
(en)
*
|
2011-02-02 |
2011-03-16 |
Fermentas Uab |
Protein production
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
AU2015328163B2
(en)
|
2014-10-09 |
2020-10-15 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable IL-2 dose regimen for treating immune disorders
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
WO2019183671A1
(en)
*
|
2018-03-28 |
2019-10-03 |
Proteomics International Pty Ltd |
Methods for measuring relative oxidation levels of a protein
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|